Market Overview

DuPont's Industrial Biosciences Unit to Buy Verdezyen's Xylose Isomerase Technology

Share:
Related DD
Billionaire Nelson Peltz's Trian Fund Holds These 11 Stocks
Nelson Peltz & Trian Nix Compromise With DuPont, Stock Rises
DuPont (DD), MCR Safety Launch New Kevlar Glove - Analyst Blog (Zacks)

Verdezyne, Inc., a privately-held industrial biotechnology company focused on producing renewable chemicals, announced the sale of its proprietary xylose isomerase technology, enabling the metabolism of 5-carbon sugars, to DuPont Industrial Biosciences, a world leader in science and innovation.

Under the terms of the sale, DuPont has purchased rights to Verdezyne's patented xylose isomerase technology, covered by U.S. Patent Nos. 8,114,974 and 8,093,037, for use in the rapidly-commercializing biofuels and biochemical fields. This technology allows the fast and complete utilization of biomass-sourced C5 sugars in production of various products of choice. This technological breakthrough was highlighted in a recent Journal of Industrial Microbiology & Biotechnology article published August 2012.

Posted-In: News M&A

 

Related Articles (DD)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→